AUTHOR=Jiménez-Juárez Rogelio , Cruz-Chávez Wendy , de Jesús-Ramírez Nayeli , Castro-Ramírez Guadalupe Ivonne , Uribe-González Itzel , Martínez-Mejía Gabriela , Ruiz-Nicolás Ricardo , Aguirre-Alvarado Charmina , Castrejón-Jiménez Nayeli Shantal , García-Pérez Blanca Estela 

TITLE=Synthesis and Antimycobacterial Activity of 2,5-Disubstituted and 1,2,5-Trisubstituted Benzimidazoles

JOURNAL=Frontiers in Chemistry

VOLUME=8

YEAR=2020

URL=https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2020.00433

DOI=10.3389/fchem.2020.00433

ISSN=2296-2646

ABSTRACT=<p>The appearance of drug-resistant strains of <italic>Mycobacterium tuberculosis</italic> and the dramatic increase in infection rates worldwide evidences the urgency of developing new and effective compounds for treating tuberculosis. Benzimidazoles represent one possible source of new compounds given that antimycobacterial activity has already been documented for some derivatives, such as those bearing electron-withdrawing groups. The aim of this study was to synthesize two series of benzimidazoles, di- and trisubstituted derivatives, and evaluate their antimycobacterial activity. Accordingly, <bold>5a</bold> and <bold>5b</bold> were synthesized from hydroxymoyl halides <bold>3a</bold> and <bold>3b</bold>, and nitro-substituted o-phenylenediamine <bold>4</bold>. Compound <bold>11</bold> was synthesized from an aromatic nitro compound, 4-chloro-1,2-phenylenediamine <bold>9</bold>, mixed with 3-nitrobenzaldehyde <bold>10</bold>, and bentonite clay. Although the synthesis of <bold>11</bold> has already been reported, its antimycobacterial activity is herein examined for the first time. 1,2,5-trisubstituted benzimidazoles <bold>7a</bold>, <bold>7b</bold>, and <bold>12</bold> were obtained from N-alkylation of <bold>5a</bold>, <bold>5b</bold>, and <bold>11</bold>. All benzimidazole derivatives were characterized by FT-IR, NMR, and HR-MS, and then screened for their <italic>in vitro</italic> antimycobacterial effect against the <italic>M. tuberculosis</italic> H37Rv strain. The N-alkylated molecules (<bold>7a</bold>, <bold>7b</bold>, and <bold>12</bold>) generated very limited <italic>in vitro</italic> inhibition of mycobacterial growth. The benzimidazoles (<bold>5a</bold>, <bold>5b</bold>, and <bold>11</bold>) showed <italic>in vitro</italic> potency against mycobacteria, reflected in minimal inhibitory concentration (MIC) values in the range of 6.25–25 μg/mL. Consequently, only the 2,5-disubstituted benzimidazoles were assessed for biological activity on mouse macrophages infected with <italic>M. tuberculosis</italic>. A good effect was found for the three compounds. The cytotoxicity assay revealed very low toxicity for all the test compounds against the macrophage cell line. According to the docking study, 2,5-disubstituted benzimidazoles exhibit high affinity for an interdomain cleft that plays a key role in the GTP-dependent polymerization of the filamentous temperature-sensitive Z (FtsZ) protein. The ability of different benzimidazoles to impede FtsZ polymerization is reportedly related to their antimycobacterial activity. On the other hand, the 1,2,5-trisubstituted benzimidazoles docked to the N-terminal of the protein, close to the GTP binding domain, and did not show strong binding energies. Overall, <bold>5a</bold>, <bold>5b</bold>, and <bold>11</bold> proved to be good candidates for <italic>in vivo</italic> testing to determine their potential for treating tuberculosis.</p>